Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: A multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1477-1484

  Chang, Peter Mu Hsin ^a,b   Tzeng, Cheng Hwai ^a,b   Chen, Ming Huang ^a,b   Tsao, Chao Jung ^c   Su, Wu Chou ^d   Hwang, Wei Shuo ^c   Chang, Yi Fang ^e   Chang, Shyue Yih ^b   Yang, Muh Hwa ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Docetaxel; Head and neck squamous cell carcinoma; Metastatic; Recurrent

Indexed keywords

CISPLATIN; DOCETAXEL; TYXAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DEATH; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TAXOIDS;

EID: 82455188380     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1645-5     Document Type: Article

References (36)

1. D Hardisson 2003 Molecular pathogenesis of head and neck squamous cell carcinoma Eur Arch Otorhinolaryngol 260 502 508 12736744 10.1007/s00405-003- 0581-3 (Pubitemid 37363578)
2. Department of Health, the Executive Yuan, R.O.C. Cancer Registry Annual Report in Taiwan Area (2005)
3. EE Vokes RR Weichselbaum SM Lippman WK Hong 1993 Head and neck cancer N Engl J Med 328 184 194 8417385 10.1056/NEJM199301213280306 1:STN:280: DyaK3s7gvFCisg%3D%3D (Pubitemid 23021505)
4. C Jacobs G Lyman E Velez-Garcia KS Sridhar W Knight H Hochster LT Goodnough JE Mortimer LH Einhorn Schacter Let 1992 A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 257 263 1732427 1:STN:280:DyaK387itF2gtA%3D%3D
5. AA Forastiere B Metch DE Schuller JF Ensley LF Hutchins P Triozzi JA Kish S McClure E VonFeldt SK Williamson 1992 Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study J Clin Oncol 10 1245 1251 1634913 1:STN:280:DyaK38zktFWguw%3D%3D
6. M Clavel JB Vermorken F Cognetti P Cappelaere PH de Mulder JH Schornagel EA Tueni J Verweij J Wildiers M Clerico 1994 Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group Ann Oncol 5 521 526 7522527 1:STN:280: DyaK2M%2FgtFGrtg%3D%3D (Pubitemid 24223504)
7. L Licitra LD Locati P Bossi 2008 Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options Ann Oncol 19 Suppl 7 vii200 vii203 18790949 10.1093/annonc/mdn456
8. JB Vermorken R Mesia F Rivera E Remenar A Kawecki S Rottey J Erfan D Zabolotnyy HR Kienzer D Cupissol F Peyrade M Benasso I Vynnychenko D De Raucourt C Bokemeyer A Schueler N Amellal R Hitt 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 1116 1127 18784101 10.1056/NEJMoa0802656 1:CAS:528:DC%2BD1cXhtFWrsrnI
9. MR Posner DM Hershock CR Blajman E Mickiewicz E Winquist V Gorbounova S Tjulandin DM Shin K Cullen TJ Ervin BA Murphy LE Raez RB Cohen M Spaulding RB Tishler B Roth RC Viroglio V Venkatesan I Romanov S Agarwala KM Harter M Dugan A Cmelak AM Markoe PW Read L Steinbrenner AD Colevas CM Norris Jr RI Haddad 2007 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705 1715 17960013 10.1056/NEJMoa070956 1:CAS:528: DC%2BD2sXht1ansLvI (Pubitemid 350005152)
10. JB Vermorken E Remenar CV Herpen T Gorlia R Mesia M Degardin JS Stewart S Jelic J Betka JH Preiss DV den Weyngaert A Awada D Cupissol HR Kienzer A Rey I Desaunois J Bernier JL Lefebvre 2007 Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695 1704 17960012 10.1056/NEJMoa071028 1:CAS:528:DC%2BD2sXht1ansLvP (Pubitemid 350005151)
11. G Catimel J Verweij V Mattijssen A Hanauske M Piccart J Wanders H Franklin N Le Bail M Clavel SB Kaye 1994 Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group Ann Oncol 5 533 537 7918125 1:STN:280:DyaK2M%2FgtFGrtA%3D%3D
12. AI Dreyfuss JR Clark CM Norris RM Rossi JW Lucarini PM Busse MD Poulin L Thornhill R Costello MR Posner 1996 Docetaxel: an active drug for squamous cell carcinoma of the head and neck J Clin Oncol 14 1672 1678 8622087 1:CAS:528:DyaK28XjtFKitr8%3D (Pubitemid 26134226)
13. C Couteau N Chouaki S Leyvraz D Oulid-Aissa A Lebecq C Domenqe V Groult S Bordessoule F Janot M DeForni JP Armand 1999 A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck Br J Cancer 81 457 462 10507770 10.1038/sj.bjc.6690715 1:CAS:528:DyaK1MXms12mu7g%3D (Pubitemid 29458799)
14. R Hitt ML Amador M Quintela-Fandino A Jimeno O delVal S Hernando H Cortes-Funes 2006 Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Cancer 106 106 111 16329139 10.1002/cncr.21579 1:CAS:528:DC%2BD28XptF2rug%3D%3D (Pubitemid 43032554)
15. AD Colevas S Adak PC Amrein JJ Barton R Costello MR Posner 2000 A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck Ann Oncol 11 535 539 10907945 10.1023/A:1008355413788 1:STN:280:DC%2BD3M%2Fms1OhtQ%3D%3D (Pubitemid 30431374)
16. D Genet D Cupissol G Calais P Bontemps H Bourqeois JP Dutin MH Philippi B Bendahmane M Mallard-Carre N Tubiana-Mathieu 2004 Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study Am J Clin Oncol 27 472 476 15596913 10.1097/01.coc.0000136017.13633.b0 1:CAS:528:DC%2BD2cXps1altbo%3D (Pubitemid 39371941)
17. JL Labourey D Cupissol G Calais JM Tourani F Kohser C Borel JC Eymard N Germann N Tubiana-Mathieu 2007 Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study Am J Clin Oncol 30 278 282 17551305 10.1097/01.coc.0000258117.75487.2b 1:CAS:528:DC%2BD2sXnvVGiurs%3D (Pubitemid 46884148)
18. I Robert A Haddad A David Van Echo 2003 Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer Cancer Chemother Pharmacol 52 303 306 10.1007/s00280-003-0673-1 (Pubitemid 37352596)
19. P Schoffski G Catimel AS Planting JP Droz J Verweij D Schrijvers L Gras A Schrijvers J Wanders AR Hanauske 1999 Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group Ann Oncol 10 119 122 10076732 10.1023/A:1008360323986 1:STN:280:DyaK1M7ns1Shug%3D%3D (Pubitemid 29090602)
20. L Specht SK Larsen HS Hansen 2000 Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck Ann Oncol 11 845 849 10997812 10.1023/A:1008355315205 1:STN:280:DC%2BD3cvks1SgtQ%3D%3D
21. BS Glisson BA Murphy G Frenette FR Khuri AA Forastiere 2002 Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck J Clin Oncol 20 1593 1599 11896109 10.1200/JCO.20.6.1593 1:CAS:528:DC%2BD38XivFeitrg%3D (Pubitemid 34260540)
22. F Caponigro E Massa L Manzione G Rosati M Biglietto L De Lucia C Sguotti P Sganga A Avallone P Cornelia G Mantovani G Cornelia 2001 Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) Ann Oncol 12 199 202 11300324 10.1023/A:1008322415335 1:STN:280:DC%2BD3M3gvFansQ%3D%3D (Pubitemid 32223868)
23. WE Samlowski J Moon JP Kuebler CR Nichols DR Gandara H Ozer SK Williamson JN Atkins DE Schuller JF Ensley 2007 Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study Cancer Invest 25 182 188 17530488 10.1080/07357900701209061 1:CAS:528:DC%2BD2sXlvVSiurw%3D (Pubitemid 47164860)
24. O Guntinas-Lichius S Appenrodt F Veelken B Krug 2006 Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer Laryngoscope 116 613 618 16585868 10.1097/01.mlg.0000208366.34683.58 1:CAS:528:DC%2BD28XjtFOrt7k%3D (Pubitemid 44318074)
25. LS Tham NH Holford SY Hor T Tan L Wang RC Lim HS Lee SC Lee BC Goh 2007 Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4a, and constitutive androstane receptor with docetaxel pharmacokinetics Clin Cancer Res 13 7126 7132 18056193 10.1158/1078-0432.CCR-07- 1276 1:CAS:528:DC%2BD2sXhtlyitL3J (Pubitemid 350276898)
26. I Sekinea H Nokihara N Yamamoto H Kunitoh Y Ohe N Saijo T Tamura 2006 Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer Lung Cancer 53 157 164 10.1016/j.lungcan.2006.05.007 (Pubitemid 43994238)
27. T Kojima T Shimazui M Onozawa S Tsukamoto S Hinotsu N Miyanaga K Hattori K Kawai H Akaza 2004 Weekly administration of docetaxel in patients with hormone refractory prostate cancer: a pilot study on Japanese patients Jpn J Clin Oncol 34 137 141 15078909 10.1093/jjco/hyh021 (Pubitemid 43102905)
28. R Simon 1989 Optimal two-stage designs for phase II clinical trials Controlled Clin Trials 10 1 10 2702835 10.1016/0197-2456(89)90015-9 1:STN:280:DyaL1M7ps1SjsQ%3D%3D (Pubitemid 19099520)
29. PM Chang PM Chen PY Chu LW Wang SK Tai TL Tsai JL Huang YF Wang SY Chang MH Yang 2008 Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study Cancer Chemother Pharmacol 63 9 17 18343925 10.1007/s00280-008-0702-1 1:CAS:528:DC%2BD1cXhtF2kur%2FI
30. PM Specenier J Van Den Brande D Schrijvers MT Huizing S Altintas J Dyck D Van Den Weyngaert C Van Laer JB Vermorken 2009 Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck Anticancer Res 29 5137 5142 20044628 1:CAS:528:DC%2BC3cXht1Kjsrw%3D
31. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
32. T Oqawa A Terada I Hyodo A Ando Y Suzuki T Ozawa Y Haseqawa 2005 A Phase I study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck Gan To Kaqaku Ryoho 32 977 981
33. MJ Millward MJ Boyer M Lehnert S Clarke D Rischin B-C Goh J Wong E McNeil JF Bishop 2003 Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients Ann Oncol 14 449 454 12598352 10.1093/annonc/mdg118 1:STN:280: DC%2BD3s%2Fos1Glsw%3D%3D (Pubitemid 36367424)
34. KA Gelmon D Stewart KN Chi S Chia C Cripps S Huan S Janke D Ayers D Fry JA Shabbits W Walsh L McIntosh LK Seymour 2004 A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 Ann Oncol 15 1115 1122 15205207 10.1093/annonc/mdh278 1:STN:280: DC%2BD2czgt1Wjug%3D%3D (Pubitemid 39089789)
35. SY Hor SC Lee CI Wong YW Lim RC Lim LZ Wang L Fan JY Guo HS Lee BC Goh T Tan 2008 PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients Pharmacogenomics J 8 139 146 17876342 10.1038/sj.tpj.6500478 1:CAS:528:DC%2BD1cXjtlKjur4%3D (Pubitemid 351411550)
36. SJ Clarke LP Rivory 1999 Clinical pharmacokinetics of docetaxel Clin Pharmacokinet 36 99 114 10092957 10.2165/00003088-199936020-00002 1:CAS:528:DyaK1MXitFCntL0%3D (Pubitemid 29121684)